Barclays Reiterates Overweight Rating on Replimune Group (REPL), PT $17, 'We see this as a clear positive for Iovance's Amtagvi'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
Go back to Barclays Reiterates Overweight Rating on Replimune Group (REPL), PT $17, 'We see this as a clear positive for Iovance's Amtagvi'
July 22, 2025 8:19 AM EDT
false
0001737953
0001737953
2025-07-21
2025-07-21
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares... More